Skip to main content

Advertisement

SpringerLink
Log in

Angioedema with Normal Laboratory Values: The Next Step

  • ALLERGIC SKIN DISEASES (L FONACIER, SECTION EDITOR)
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

When faced with a patient with recurrent swelling, a thorough laboratory evaluation to determine the underlying etiology ensues. When the laboratory work-up is unrevealing, health care practitioners are frequently left in a quandary. This review will attempt to provide up-to-date information on how to approach the diagnosis and management of angioedema in a patient with normal laboratory values. The subtypes that will be reviewed in detail include: hereditary angioedema with normal C1 inhibitor (HAE with normal C1INH), drug-induced angioedema, and idiopathic angioedema. We present literature to aid the physician in the diagnosis and treatment of these disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Kaplan AP. Angioedema. World Allergy Organ J. 2008;1:103–13.

    Article  PubMed  Google Scholar 

  2. •• Sanchez-Borges M, Asero R, Ansotegui IJ, Baiardini I, Bernstein JA, Canonica GW, et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J. 2012;5:125–47. These are current evidence-based guidelines put forth by the World Allergy Organization..

    Article  PubMed  Google Scholar 

  3. Davis 3rd AE. The pathophysiology of hereditary angioedema. Clin Immunol. 2005;114:3–9.

    Article  PubMed  CAS  Google Scholar 

  4. Zuraw BL. Current and future therapy for hereditary angioedema. Clin Immunol. 2005;114:10–6.

    Article  PubMed  CAS  Google Scholar 

  5. Agostoni A, Aygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114:S51–S131.

    Article  PubMed  Google Scholar 

  6. Zingale LC, Beltrami L, Zanichelli A, Maggioni L, Pappalardo E, Cicardi B, et al. Angioedema without urticaria: a large clinical survey. CMAJ. 2006;175:1065–70.

    PubMed  Google Scholar 

  7. Greenberger PA. Anaphylactic and anaphylactoid causes of angioedema. Immunol Allergy Clin North Am. 2006;26:753–67.

    Article  PubMed  Google Scholar 

  8. • Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, et al. International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol. 2010;6:24. This is an excellent review on the approach to the diagnosis and management of hereditary angioedema.

    Article  Google Scholar 

  9. Zingale LC, Castelli R, Zanichelli A, Cicardi M. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. Immunol Allergy Clin North Am. 2006;26:669–90.

    Article  PubMed  Google Scholar 

  10. Campo P, Fernandez TD, Canto G, Mayorga C. Angioedema induced by angiotensin-converting enzyme inhibitors. Curr Opin Allergy Clin Immunol. 2013;13:337–44.

    Article  PubMed  CAS  Google Scholar 

  11. Clarkson B, Thompson D, Horwith M, Luckey EH. Cyclical edema and shock due to increased capillary permeability. American J Medicine. 1960;29:193–216.

    Article  CAS  Google Scholar 

  12. Fischer R, Ostendorf B, Richter J, Schneider M. Hypovolemic shock associated with generalized edema: paroxysmal non-hereditary angioedema (Clarkson syndrome). Dtsch Med Wochenschr. 2000;125:427–8.

    Article  PubMed  CAS  Google Scholar 

  13. Binkley KE, Davis 3rd A. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol. 2000;106:546–50.

    Article  PubMed  CAS  Google Scholar 

  14. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356:213–7.

    Article  PubMed  CAS  Google Scholar 

  15. •• Zuraw BL, Bork K, Binkley KE, Banerji A, Christiansen SC, Castaldo A, et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc. 2012;33 Suppl 1:S145–56.

    Article  PubMed  CAS  Google Scholar 

  16. Bork K, Gul D, Hardt J, Dewald G. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med. 2007;120:987–92.

    Article  PubMed  Google Scholar 

  17. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343:1286–9.

    Article  PubMed  CAS  Google Scholar 

  18. Cohen AJ, Laskin C, Tarlo S. C1 esterase inhibitor in pregnancy. J Allergy Clin Immunol. 1992;90:412–3.

    Article  PubMed  CAS  Google Scholar 

  19. Martin L, Degenne D, Toutain A, Ponard D, Watier H. Hereditary angioedema type III: an additional French pedigree with autosomal dominant transmission. J Allergy Clin Immunol. 2001;107:747–8.

    Article  PubMed  CAS  Google Scholar 

  20. Ogston D, Walker J, Campbell DM. C1 inactivator level in pregnancy. Thromb Res. 1981;23:453–5.

    Article  PubMed  CAS  Google Scholar 

  21. Bork K. Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Allergy, Asthma, and Clinical Immunology: official journal of the Canadian Society of Allergy and. Clin Immunol. 2010;6:15.

    Google Scholar 

  22. Bork K, Gul D, Dewald G. Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. Br J Dermatol. 2006;154:542–5.

    Article  PubMed  CAS  Google Scholar 

  23. Vitrat-Hincky V, Gompel A, Dumestre-Perard C, Boccon-Gibod I, Drouet C, Cesbron JY, et al. Type III hereditary angio-oedema: clinical and biological features in a French cohort. Allergy. 2010;65:1331–6.

    Article  PubMed  CAS  Google Scholar 

  24. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine. 1992;71:206–15.

    Article  PubMed  CAS  Google Scholar 

  25. Bouillet L, Longhurst H, Boccon-Gibod I, Bork K, Bucher C, Bygum A, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol. 2008;199(484):e1–4.

    PubMed  Google Scholar 

  26. Caballero T, Farkas H, Bouillet L, Bowen T, Gompel A, Fagerberg C, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129:308–20.

    Article  PubMed  Google Scholar 

  27. Czaller I, Visy B, Csuka D, Fust G, Toth F, Farkas H. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. European J Obstet Gynecol Reprod Biol. 2010;152:44–9.

    Article  CAS  Google Scholar 

  28. Martinez-Saguer I, Rusicke E, Aygoren-Pursun E, Heller C, Klingebiel T, Kreuz W. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol. 2010;203(131):e1–7.

    PubMed  Google Scholar 

  29. Halbmayer WM, Hopmeier P, Mannhalter C, Heuss F, Leodolter S, Rubi K, et al. C1-esterase inhibitor in uncomplicated pregnancy and mild and moderate preeclampsia. Thromb Haemost. 1991;65:134–8.

    PubMed  CAS  Google Scholar 

  30. Picone O, Donnadieu AC, Brivet FG, Boyer-Neumann C, Fremeaux-Bacchi V, Frydman R. Obstetrical complications and outcome in two families with hereditary angioedema due to mutation in the F12 gene. Obstet Gynecol Int. 2010;2010:957507.

    PubMed  Google Scholar 

  31. Bouillet L, Ponard D, Rousset H, Cichon S, Drouet C. A case of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. Br J Dermatol. 2007;156:1063–5.

    Article  PubMed  CAS  Google Scholar 

  32. Campbell SJ, Mackie IJ, Robinson GE, Machin SJ. Contact factor mediated fibrinolysis is increased by the combined oral contraceptive pill. Br J Obstet Gynaecol. 1993;100:79–84.

    Article  PubMed  CAS  Google Scholar 

  33. Fossum S, Hoem NO, Gjonnaess H, Briseid K. Contact activation factors in plasma from women on estrogen replacement therapy after ovariohysterectomy. Thromb Res. 1999;93:161–70.

    Article  PubMed  CAS  Google Scholar 

  34. Fossum S, Hoem NO, Johannesen S, Korpberget M, Nylund E, Sandem S, et al. Contact factors in plasma from women on oral contraception—significance of factor XI for the measured activity of factor XII. Thromb Res. 1994;74:477–85.

    Article  PubMed  CAS  Google Scholar 

  35. Gordon EM, Douglas JG, Ratnoff OD, Arafah BM. The influence of estrogen and prolactin on Hageman factor (factor XII) titer in ovariectomized and hypophysectomized rats. Blood. 1985;66:602–5.

    PubMed  CAS  Google Scholar 

  36. Ratnoff OD. The hormonal control of the synthesis of Hageman factor (factor XII). Phenomenology and science: friends or foes? J Lab Clin Med. 1991;117:343.

    PubMed  CAS  Google Scholar 

  37. Zuraw BL. Diagnosis and management of hereditary angioedema: an American approach. Transfus Apher Sci. 2003;29:239–45.

    Article  PubMed  Google Scholar 

  38. Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf. 2001;24:599–606.

    Article  PubMed  CAS  Google Scholar 

  39. Sarkar P, Nicholson G, Hall G. Brief review: angiotensin converting enzyme inhibitors and angioedema: anesthetic implications. Can J Anaesth. 2006;53:994–1003.

    Article  PubMed  Google Scholar 

  40. Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother. 2000;34:526–8.

    Article  PubMed  CAS  Google Scholar 

  41. Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf. 1998;18:171–88.

    Article  PubMed  CAS  Google Scholar 

  42. Haymore BR, Yoon J, Mikita CP, Klote MM, DeZee KJ. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol. 2008;101:495–9.

    Article  PubMed  Google Scholar 

  43. Banerji A, Clark S, Blanda M, LoVecchio F, Snyder B, Camargo Jr CA. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol. 2008;100:327–32.

    Article  PubMed  Google Scholar 

  44. Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am. 2006;26:725–37.

    Article  PubMed  Google Scholar 

  45. Gainer JV, Stein CM, Neal T, Vaughan DE, Brown NJ. Interactive effect of ethnicity and ACE insertion/deletion polymorphism on vascular reactivity. Hypertension. 2001;37:46–51.

    Article  PubMed  CAS  Google Scholar 

  46. Sondhi D, Lippmann M, Murali G. Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital. Chest. 2004;126:400–4.

    Article  PubMed  CAS  Google Scholar 

  47. Gosmanov AR, Fontenot EC. Sitagliptin-associated angioedema. Diabetes Care. 2012;35:e60.

    Article  PubMed  Google Scholar 

  48. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54:516–23.

    Article  PubMed  CAS  Google Scholar 

  49. Skalli S, Wion-Barbot N, Baudrant M, Lablanche S, Benhamou PY, Halimi S. Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report. Diabet Med. 2010;27:486–7.

    Article  PubMed  CAS  Google Scholar 

  50. Frigas E, Nzeako UC. Angioedema. Pathogenesis, differential diagnosis, and treatment. Clin Rev Allergy Immunol. 2002;23:217–31.

    Article  PubMed  Google Scholar 

  51. Bork K, Wulff K, Hardt J, Witzke G, Staubach P. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol. 2009;124:129–34.

    Article  PubMed  CAS  Google Scholar 

  52. Bell CG, Kwan E, Nolan RC, Baumgart KW. First molecular confirmation of an Australian case of type III hereditary angioedema. Pathology. 2008;40:82–3.

    Article  PubMed  Google Scholar 

  53. Prieto A, Tornero P, Rubio M, Fernandez-Cruz E, Rodriguez-Sainz C. Missense mutation Thr309Lys in the coagulation factor XII gene in a Spanish family with hereditary angioedema type III. Allergy. 2009;64:284–6.

    Article  PubMed  CAS  Google Scholar 

  54. Bouillet L, Boccon-Gibod I, Ponard D, Drouet C, Cesbron JY, Dumestre-Perard C, et al. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann Allergy Asthma Immunol. 2009;103:448.

    Article  PubMed  Google Scholar 

  55. Herrmann G, Schneider L, Krieg T, Hunzelmann N, Scharffetter-Kochanek K. Efficacy of danazol treatment in a patient with the new variant of hereditary angio-oedema (HAE III). Br J Dermatol. 2004;150:157–8.

    Article  PubMed  CAS  Google Scholar 

  56. Smith Jr SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2006;47:2130–9.

    Article  PubMed  Google Scholar 

  57. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:S1-290.

    Google Scholar 

  58. Beltrami L, Zanichelli A, Zingale L, Vacchini R, Carugo S, Cicardi M. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J Hypertens. 2011;29:2273–7.

    Article  PubMed  CAS  Google Scholar 

  59. Sachdeva S, Gupta V, Amin SS, Tahseen M. Chronic urticaria. Indian J Dermatol. 2011;56:622–8.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Mark Davis-Lorton is on the speaker’s bureau for and has served as a primary investigator for clinical trials sponsored by Dyax Corp. and Viropharma Inc.

Janelle Sher declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Rheumatology, Allergy & Immunology, Winthrop University, 120 Mineola Blvd., Suite 410, Mineola, NY, 11501, USA

    Janelle Sher & Mark Davis-Lorton

Authors
  1. Janelle Sher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Davis-Lorton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janelle Sher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sher, J., Davis-Lorton, M. Angioedema with Normal Laboratory Values: The Next Step. Curr Allergy Asthma Rep 13, 563–570 (2013). https://doi.org/10.1007/s11882-013-0383-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-013-0383-7

Keywords

Search

Navigation